Research programme: peptide therapeutics - Phoundry Pharmaceuticals
Latest Information Update: 18 Mar 2016
At a glance
- Originator Phoundry Pharmaceuticals
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 18 Mar 2016 Discontinued for Diabetes mellitus in USA (unspecified route)
- 18 Mar 2016 Discontinued for Obesity in USA (unspecified route)
- 24 Sep 2015 Early research in Diabetes mellitus in USA (unspecified route)